[1] Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature, 1996, 379(6564): 458-460.  doi: 10.1038/379458a0
[2] Smanik P, Liu Q, Furminger TL, et al. Cloning of the human sodium lodide symporter. Biochem Biophys Res Commun, 1996, 226(2): 339-345.  doi: 10.1006/bbrc.1996.1358
[3] Scott DA, Wang R, Kreman TM, et al. The Pendred syndrome gene encodes a chloride-iodide transport protein. Nat Genet, 1999, 21(4): 440-443.  doi: 10.1038/7783
[4] Rodriguez AM, Perron B, Lacroix L, et al. Identification and characterization of a putative human iodide transporter located at the apical membrane of thyrocytes. J Clin Endocrinol Metab, 2002, 87(7): 3500-3503.  doi: 10.1210/jcem.87.7.8797
[5] Lazar V, Bidart JM, Caillou B, et al. Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J Clin Endocrinol Metab, 1999, 84(9): 3228-3234.
[6] Dohán O, Baloch Z, Bánrévi Z, et al. Rapid communieation: predominant intracellular overexpression of the Na+/I- symporter (NIS) in a large sampling of thyroid cancer case. J Clin Endocrinol Metab, 2001, 86(6): 2697-2700.
[7] De La Vieja A, Dohán O, Levy O, et al. Molecular analysis of the sodium/iodide symporter: impact on thyroid and extrathyroid pathophysiology. Physiol Rev, 2000, 80(3): 1083-1105.  doi: 10.1152/physrev.2000.80.3.1083
[8] Yokomori N, Tawata M, Saito T, et al. Regulation of the rat thyrotropin receptor gene by the methylation-sensitive transcription factor GA-binding protein. Mol Endocrinol, 1998, 12(8): 1241-1249.  doi: 10.1210/mend.12.8.0142
[9] Peyrottes I, Navarro V, Ondo-Mendez A, et al. Immunoanalysis indicates that the sodium iodide symporter is not overexpressed in intracellular compartments in thyroid and breast cancers. Eur J Endocrinol, 2009, 160(2): 215-225.  doi: 10.1530/EJE-08-0505
[10] Venkataraman GM, Yatin M, Marcinek R, et al. Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na+/I- symporter gene methylation status. J Clin Endocrinol Metab, 1999, 84(7): 2449-2457.
[11] Kitazono M, Robey R, Zhan Z, et al. Low concentrations of the histone deacetylase inhibitor, depsipeptide(FR901228), increase expression of the Na+/I- symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab, 2001, 86(7): 3430-3435.
[12] Zarnegar R, Brunaud L, Kanauchi H, et al. Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using Trichostatin A, a histone deacetylase inhibitor. Surgery, 2002, 132(6): 984-990.  doi: 10.1067/msy.2002.128690
[13] Simon D, Körber C, Krausch M, et al. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. Eur J Nucl Med Mol Imaging, 2002, 29(6): 775-782.  doi: 10.1007/s00259-001-0737-6
[14] Haugen BR, Larson LL, Pugazhenthi U, et al. Retinoic acid and retinoid X receptors are differentially expressed in thyroid cancer and thyroid carcinoma cell lines and predict response to treatment with retinoids. J Clin Endocrinol Metab, 2004, 89(1): 272-280.  doi: 10.1210/jc.2003-030770
[15] Kogai T, Schultz JJ, Johnson LS, et al. Retinoic acid induces sodium/iodide symporter gene expression and radioiodide uptake in the MCF-7 breast cancer cell line. Proc Natl Acad Sci USA, 2000, 97(15): 8519-8524.  doi: 10.1073/pnas.140217197
[16] Kim KI, Kang JH, Chung JK, et al. Doxorubicin enhances the expression of transgene under control of the CMV promoter in anaplastic thyroid carcinoma cells. J Nucl Med, 2007, 48(9): 1553-1561.  doi: 10.2967/jnumed.106.038612
[17] Condreay JP, Witherspoon SM, Clay WC, et al. Transient and stable gene expression in mammalian cells transduced with a recombinant baculovirus vector. Proc Natl Acad Sci USA, 1999, 96(1): 127-132.  doi: 10.1073/pnas.96.1.127
[18] Mian C, Barollo S, Pennelli G, et al. Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake. Clin Endocrinol (Oxf), 2008, 68(1): 108-116.  doi: 10.1111/j.1365-2265.2007.03008.x
[19] Durante C, Puxeddu E, Ferretti E, et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab, 2007, 92(7): 2840-2843.  doi: 10.1210/jc.2006-2707
[20] Furuya F, Shimura H, Miyazaki A, et al. Adenovirus-mediated transfer of thyroid transcription factor-1 induces radioiodide organ-ification and retention in thyroid cancer cells. Endocrinology, 2004, 145(11): 5397-5405.  doi: 10.1210/en.2004-0631
[21] Huang M, BatraRK, Kogai T, et al. Ectopic expression of the thyroperoxidase gene augments radioiodide uptake and retention mediated by the sodium iodide symporter in non-small cell lung cancer. Cancer Gene Ther, 2001, 8(8): 612-618.  doi: 10.1038/sj.cgt.7700354
[22] Boland A, Magnon C, Filetti S, et al. Transposition of the thyroid iodide uptake and organification system in nonthyroid tumor cells by adenoviral vector-mediated gene transfers. Thyroid, 2002, 12(1): 19-26.  doi: 10.1089/105072502753451922
[23] Elisei R, Vivaldi A, Ciampi R, et al. Treatment with drugs able to reduce iodine efflux significantly increases the intracellular reten-tion time in thyroid cancer cells stably transfected with sodium iodide symporter complementary deoxyribonucleic acid. J Clin Endocrinol Metab, 2006, 91(6): 2389-2395.  doi: 10.1210/jc.2005-2480
[24] Yoon JK, Park BN, Paik JY, et al. Effects of theophylline on radioiodide uptake in MCF-7 breast cancer and NIS gene-transduced SNU-C5 colon cancer cells. Cancer Biother Radiopharm, 2009, 24(2): 201-208.  doi: 10.1089/cbr.2008.0555
[25] Lee JM, Zemans RL, Hejazi M, et al. Modulation of thyroidal radioiodine uptake by theophylline. Exp Mol Pathol, 2004, 77(2): 116-120.  doi: 10.1016/j.yexmp.2004.05.002
[26] Dingli D, Bergert ER, Bajzer Z, et al. Dynamic iodide trapping by tumor cells expressing the thyroidal sodium iodide symporter. Biochem Biophys Res Commun, 2004, 325(1): 157-166.  doi: 10.1016/j.bbrc.2004.09.219
[27] Nakamoto Y, Saga T, Misaki T, et al. Establishment and charac-terization of a breast cancer cell line expressing Na+/I-symporters for radioiodide concentrator gene therapy. J Nucl Med, 2000, 41(11): 1898-1904.
[28] Smit JW, Schröder-van der Elst JP, Karperien M, et al. Iodide kinetics and experimental 131I therapy in a xenotransplanted human sodium-iodide symporter-transfected human follicular thyroid carinoma cell line. J Clin Endocrinol Metab, 2002, 87(3): 1247-1253.  doi: 10.1210/jcem.87.3.8307
[29] Josefsson M, Evilevitch L, Weström B, et al. Sodium-iodide sym-porter mediates iodide secretion in rat gastric mucosa in vitro. Exp Biol Med (Maywood), 2006, 231(3): 277-281.  doi: 10.1177/153537020623100306